LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Search

Glaukos Corp

Suletud

SektorTervishoid

109.48 2.61

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

107.61

Max

109.48

Põhinäitajad

By Trading Economics

Sissetulek

3.4M

-16M

Müük

9.4M

134M

Aktsiakasum

-0.16

Kasumimarginaal

-12.155

Töötajad

995

EBITDA

8.1M

-570K

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+27.99% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

17. veebr 2026

Turustatistika

By TradingEconomics

Turukapital

2.2B

6.5B

Eelmine avamishind

106.87

Eelmine sulgemishind

109.48

Uudiste sentiment

By Acuity

50%

50%

106 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Glaukos Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

28. jaan 2026, 18:25 UTC

Suurimad hinnamuutused turgudel

Glaukos Shares Rise After FDA Approves NDA Supplement for iDose TR

Võrdlus sarnastega

Hinnamuutus

Glaukos Corp Prognoos

Hinnasiht

By TipRanks

27.99% tõus

12 kuu keskmine prognoos

Keskmine 140.11 USD  27.99%

Kõrge 165 USD

Madal 122 USD

Põhineb 11 Wall Streeti analüütiku instrumendi Glaukos Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

11 ratings

11

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

87.61 / 93Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

106 / 351 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
help-icon Live chat